Evidence map›Paper›PMID 34504860›Full record

ArticleFrontiers in nutrition2021

Adjunct n-3 Long-Chain Polyunsaturated Fatty Acid Treatment in Tuberculosis Reduces Inflammation and Improves Anemia of Infection More in C3HeB/FeJ Mice With Low n-3 Fatty Acid Status Than Sufficient n-3 Fatty Acid Status.

Frank E A Hayford, Robin C Dolman, Mumin Ozturk, Arista Nienaber, Cristian Ricci, Du Toit Loots, Frank Brombacher, Renée Blaauw, Cornelius M Smuts, Suraj P Parihar and 1 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in nutrition, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07118059 (Effects of Adjunct Omega-3 Long-chain Polyunsaturated Fatty Acids in Pulmonary Tuberculosis Patients), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07118059 phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Effects of Adjunct Omega-3 Long-chain Polyunsaturated Fatty Acids in Pulmonary Tuberculosis Patients: An Early Bactericidal Activity and Inflammatory Activity Trial

TypeinterventionalSponsorNorth-West University, South AfricaRan2025 to 2026Enrolled40ConditionsTuberculosis, Inflammation Biomarkers, Liver Function Tests, Iron StatusArmsOmega-3 (EPA+DHA), Placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Frank E A HayfordCentre of Excellence for Nutrition, North-West University, Potchefstroom, South Africa.
Robin C DolmanCentre of Excellence for Nutrition, North-West University, Potchefstroom, South Africa.
Mumin OzturkInternational Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town-Component, University of Cape Town, Cape Town, South Africa.
Arista NienaberCentre of Excellence for Nutrition, North-West University, Potchefstroom, South Africa.
Cristian RicciPediatric Epidemiology, Department of Pediatrics, Medical Faculty, Leipzig University, Leipzig, Germany.
Du Toit LootsLaboratory of Infectious Disease Metabolomics, Human Metabolomics, North-West University, Potchefstroom, South Africa.
Frank BrombacherInternational Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town-Component, University of Cape Town, Cape Town, South Africa.
Renée BlaauwDivision of Human Nutrition, Stellenbosch University, Cape Town, South Africa.
Cornelius M SmutsCentre of Excellence for Nutrition, North-West University, Potchefstroom, South Africa.
Suraj P PariharInternational Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town-Component, University of Cape Town, Cape Town, South Africa.
Linda MalanCentre of Excellence for Nutrition, North-West University, Potchefstroom, South Africa.
North-West University · ZAInternational Centre for Genetic Engineering and Biotechnology · ZALeipzig University · DEStellenbosch University · ZAUniversity of Cape Town · ZAWellcome Centre for Infectious Diseases Research in Africa · ZA

Funding

Wellcome Trust
6 · The paper itself

Abstract

Populations at risk for tuberculosis (TB) may have a low n-3 polyunsaturated fatty acid (PUFA) status. Our research previously showed that post-infection supplementation of n-3 long-chain PUFA (LCPUFA) in TB without TB medication was beneficial in n-3 PUFA sufficient but not in low-status C3HeB/FeJ mice. In this study, we investigated the effect of n-3 LCPUFA adjunct to TB medication in TB mice with a low compared to a sufficient n-3 PUFA status. Mice were conditioned on an n-3 PUFA-deficient (n-3FAD) or n-3 PUFA-sufficient (n-3FAS) diet for 6 weeks before TB infection. Post-infection at 2 weeks, both groups were switched to an n-3 LCPUFA [eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA)] supplemented diet and euthanized at 4- and 14- days post-treatment. Iron and anemia status, bacterial loads, lung pathology, lung cytokines/chemokines, and lung lipid mediators were measured. Following 14 days of treatment, hemoglobin (Hb) was higher in the n-3FAD than the untreated n-3FAS group (

Indexed as

adjunct therapyC3HeB/FeJ TB modelfatty acid statusimmuno-nutritionn-3 LCPUFAtuberculosis

Identifiers

PMID34504860
PMCPMC8421789
OpenAlexW3195208685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.